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Abstract
Morphine, a highly potent analgesic, is prescribed for the treatment of severe pain associated with cancer. Several in vitro and animal studies suggest that morphine is involved both in promoting and inhibiting tumor 
growth. Our aim was to test the outcome of adding morphine to the culture media of cells from two of the most 
widely used breast cancer cell lines. MCF-7 and T47D cells were seeded into 96-well microplates and cultured for 
24 hours in MEM and RPMI-1640 media respectively. Afterwards, cells were exposed for 24, 48 or 72 hours to 
media containing morphine at the following concentrations: 0.05, 0.075, 0.1, 0.25, 0.5, 0.75, 1 µM. Cell viability was 
assessed by the MTT colorimetric method. After exposure of MCF-7 cells to morphine for 24 and 48 hours, viability 
was similar to the control while, after 72 hours, this parameter was significantly enhanced at 0.75 µM and 1 µM. 
Survival of T47D cells in the first 24 hours was significantly (p<0.05) increased by the presence of 1 µM morphine, 
while an increased exposure time did not improve the outcome. Our results show that morphine can increase 
viability of breast cancer cells, depending on concentration, exposure time and cell origin.
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Introduction
Breast cancer is the most common cancer in 
women (Miller et al., 2019), death being usually 
caused by recurrence and metastasis (Ecimovic 
et al., 2011). One of the most common symptoms 
of cancer is pain, with 50-80% of cancer patients 
experiencing some degree of pain (Tuerxun and 
Cui, 2018).
Morphine was isolated in the 19th century 
by Sertürner from opium (Huxtable and Schwarz, 
2001), the dried latex of the opium poppy, Papaver 
somniferum which has been cultivated for over 
3000 years (Perea-Sasiaín, 2008). Opioids have a 
long history as treatment for diarrhea and pain 
(Zhang et al., 2008). Their potent analgesic and 
sedative effects make them widely used in clinical 
practice (Doornebal et al., 2015). Morphine is used 
to manage pain but also for anesthetic procedures 
in cancer patients undergoing surgery (Zhang et 
al., 2018).
The way morphine influences tumors, either 
by stimulating or inhibiting growth has been 
under debate, with in vivo and in vitro studies 
weighing on either side (Tuerxun and Cui, 2018). 
Retrospective studies reported that patients who 
received general anesthesia with large amounts 
of opioids showed more cancer progression or 
recurrence than patients who received regional 
anesthesia or a lower amount of opioids (Biki et al., 
2008; Exadaktylos et al., 2006; Maher et al., 2014; 
124
Bulletin UASVM Animal Science and Biotechnologies 76 (2) / 2019
MICLEA et al.
Scavonetto et al., 2014). This caused significant 
alarm for the use of morphine especially in lung, 
breast and prostate cancers.
Opioids have been shown to promote 
angiogenesis and increase breast cancer 
progression (Bimonte et al., 2015; Gupta et al., 
2002), to accelerate the growth of tumour cells 
and induce metastasis in lung (Wang et al., 2015) 
and nasopharyngeal tumors (Cao et al., 2016). 
Morphine can also inhibit immune cell functions 
and cause immunosuppression (Gach et al., 2011). 
On the other hand, Kim et al. (2016) found that 
morphine may suppress progression of several 
lung cancer cell lines. Additional studies have 
reported that opioids can inhibit gastric cancer 
progression in vitro (Qin et al., 2012), may induce 
apoptosis in colon cancer (Palma et al., 2015; 
Zhang et al., 2014) and do not enhance breast 
cancer expansion (Chen et al., 2017; Doornebal et 
al., 2015).
Studies of morphine effects in breast cancer 
have often yielded contradictory results (Juneja, 
2014), though it has become apparent that it plays 
a dual role in the regulation of tumors (Tuerxun 
and Cui, 2018).
Given the conflicting nature of the currently 
available evidence, our aim was to test the outcome 
of adding morphine to the culture media of cells 
from two of the most widely used breast cancer cell lines.
Materials and Methods
Materials
Culture media MEM and RPMI-1640 were 
acquired from Biochrom (Merck, Darmstadt, 
Germany). Morphine hydrochloride (20 mg/ml) 
solution was obtained from Zentiva (Prague, Czech 
Republic). Human recombinant insulin and the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) reagent were obtained 
from Sigma-Aldrich (Taufkirchen, Germany).
Cell lines and cell culture
Both cell lines were obtained from The Global 
Bioresource Center (American Type Culture 
Collection – ATCC). MCF7 cells maintained in MEM 
supplemented with 0.01 mg/ml insulin while 
T47D were cultured in RPMI-1640.
MTT assay for cell viability
The effects of morphine on cells were assessed 
by the MTT colorimetric method (Mosmann, 1983). 
MCF-7 and T47D cells were seeded into 96-well 
microplates at a density of 3.5-4×103 cells/well 
and kept in their respective media for 24 hours. 
Morphine hydrochloride was added to the culture 
medium for each cell type to achive the following 
final concentrations: 0.05, 0.075, 0.1, 0.25, 0.5, 
0.75, 1 µM and the cells were incubated for 24, 48 
or 72 hours. At the end of the these intervals cells 
were washed once with phosphate buffered saline 
(PBS) which was then replaced with a MTT solution 
in PBS (0.5 mg/ml) and incubated for 1 hour. Cells 
were lysed and formazan particles were solubilized 
with 150 µl dimethyl sulfoxide. The absorbance 
was read with the HT Synergy microplate plate 
reader (BioTek Instruments, USA) at 550 nm and 
expressed relative to the background absorbance 
read at 630 nm. Hydrogen peroxide was used as 
a positive control at a concentration of 100 µM 
and experiments were repeated 3 times. Results 
from the assay were reported as percentages of 
an untreated control. One-way ANOVA followed by 
Tukey multiple comparisons test was performed 
using Graph Pad Prism version 8.0.0 for Windows 
(GraphPad Software, San Diego, California USA).
Results and Discussion
Contradictory effects of morphine on the 
viability and multiplication of cancer cells have 
been reported both in vivo and in vitro. In this 
context we sought to investigate the outcome of its 
addition to the culture media of breast cancer cell 
lines MCF7 and T47D. The opioid concentrations 
were close to those reported in the plasma of 
cancer patients receiving chronic morphine 
treatment for pain relief (0.9-3.4 µM) (Tegeder 
et al., 2003) and to the baseline concentration of 
morphine in cerebrospinal fluid of approximately 
0.4 µM detected by Smith et al. (1999).
We found that morphine increased the viability 
of MCF7 cells in a dose dependent manner beyond 
what was observed for untreated cells (Fig. 1). 
This effect was visible at 24 hours starting from 
the lowest concentrations. However, it became 
statistically significant at 72 hours, particularly for 
0.75 µM and 1 µM. On the other hand, morphine 
seemed to have little effect on cell viability at 48 hours.
In T47D cells low morphine concentrations 
(0.05, 0.075 and 0.1 µM) resulted in percentages 
similar to the control for all time frames (Fig. 2). 
However, starting from 0.25 µM morphine and 
an exposure of 24 hours, cell viability reached a 
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statistically significant level for 1 µM. At 72 hours 
the overall trend was similar but differences 
between treatments were not so marked. At 48 
hours, the situation was comparable to the one 
observed for MCF7 cells.
The similar situation observed for both cell 
types at 48 hours could be caused by morphine 
which may inhibit their growth at this exposure 
interval before cells can recuperate at 72 hours.
Our results regarding MCF7 cells are similar 
to those of Ecimovic et al. (2011) who proved 
that clinical concentrations of morphine directly 
stimulate migration and proliferation of breast 
adenocarcinoma cells (MCF7 and MDA-MB-231 
cell lines) by increasing expression of the NET1 
gene in a mechanism that does not involve opioid 
receptors. It has also been shown that morphine can induce chemoresistance and promote tumor 
growth in MCF7 cells (Niu et al., 2015) and that 
clinically relevant concentrations of morphine can 
increase breast cancer progression (Bimonte et al., 
2015). In vivo this effect would be supported by 
the proangiogenic activity of morphine found by 
Gupta et al. (2002).  
Hatsukari et al. (2007) found that clinical 
concentrations of morphine similar to ours 
induced apoptosis and necrosis in MCF7 cells after 
a much shorter exposure time of only 4 hours 
while cytotoxic activity was visible in the mM 
range. However, the concentrations we employed 
increased MCF7 proliferation during long exposure 
such as 72 hours. 
In the work of Chen et al. (2017) morphine 
inhibited cell growth by blocking the cell 
cycle and promoting apoptosis in MCF-7 cells. 
Concentrations over 10 µM inhibited proliferation 
of MCF7 cells while concentrations over 0.5 mM 
caused cell death, via a p53-dependent mechanism 
(Tegeder et al., 2003). The contrasting effects of 
morphine observed in diffent studies could result 
Figure 2. Effect of morphine on T47D cells at 24, 48 and 72 hours. Different letters between means from different 
groups denote significant differences (p < 0.05).
Figure 1. Effect of morphine on MCF7 cells at 24, 48 and 72 hours. Different letters between means from 
different groups denote significant differences (p < 0.05).
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from different mechanisms (with or without opioid 
receptors) or from the combination of dose and 
exposure time. Interestingly, the work of Gonzalez-
Nunez et al. (2014) in the neuroblastoma SH-SY5Y 
cell line proposes a dual effect of morphine, with 
low doses (0.01 µM) promoting cell proliferation, 
while higher doses (1µM) would inhibit cell 
proliferation.
The different effects of morphine in the two 
cell lines could be ascribed to the presence of 
different receptors on their surface. These would 
induce contrasting reactions depending on cell 
type. Opioid receptors contain three subtypes, μ, 
κ, and δ which modulate a variety of physiological 
functions such as pain regulation, emotional tone, 
and cognitive functions (Trescot et al.,  2008). They 
can be found both in neural tissues and extraneural 
tissues (spleen, stomach, lung, pancreas, liver, 
heart, blood, and blood vessels) (Chaturvedi et al., 
2000).
Hatzoglou et al. (1996) showed that opioids 
inhibit T47D cell growth, a mechanism mediated 
through κ- and δ-opioid receptors. Their research 
also showed that T47D cell have no μ-receptors 
which probably accounts for their different 
behavior when exposed to morphine. In contrast 
μ-opioid sites have been identified in MCF7 cells 
(Maneckjee et al., 1990) and their presence 
has been shown to promote tumor growth and 
metastasis (Mathew et al., 2011). This difference in 
receptors could explain the contrasting responses 
of the two cell lines, even if both are estrogen 
receptor-positive.
Conclusion
Our experiment shows that morphine acts 
on breast cancer cell viability depending on 
concentration, exposure time and cell origin, even 
if both cell lines belong to the same molecular 
subtype of breast cancer,. The mechanism used by 
opioids to influence cancer cell development is still 
unclear and more studies should be undertaken to 
clarify it.
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